ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...
Study reveals that sleep traits predict over 15% of body characteristics across 15 physiological systems, with visceral fat, ...
The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...
On today’s CT BUZZ, Host Natasha Lubczenko sat down with Dr. Zach Korwin, owner of Sleep Stratford, to discuss an innovative ...
According to statistics by the American Association of Medicine, the disorder sleep apnea affects approximately 30 million US ...
Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...
A board-certified sleep medicine specialist reviews the history of wearable sleep trackers and explains how clinicians ...
Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...
A new survey published today reveals that 70% of women report that their sleep is impacting their mental health, while a ...
Delays in dreaming might be an early warning sign of Alzheimer’s disease.People who take significantly longer to ente ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback